In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump ...

Agencies such as FDA, Centers for Disease Control (CDC), Health and Human Services (HHS), and The Center for Drug Evaluation ...

Soley Therapeutics’ co-founder and CEO Yerem Yeghiazarians, MD, spoke with Pharmaceutical Executive about the unique approach ...

Building out a robust competency-based training system requires more upfront planning and concentrated effort. It will allow ...

Most importantly, pharmaceutical companies that negotiated agreements with the Trump administration for its Most Favored ...

The deal continues Shionogi’s streak of acquisitions to begin 2026, as the company began the year acquiring $2.1 Billion ViiV ...

Regulators are shifting antitrust scrutiny in healthcare from market share and pricing toward how vertically integrated ...

You have 16 companies that have entered into these voluntary deals with the White House HHS, and CMS. They are agreeing to ...

Christopher Locher, PhD, CEO, Versatope Therapeutics, Inc., discusses how emerging vaccine platforms are advancing the pursuit of a universal influenza vaccine, while highlighting the scientific, ...

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...